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ABSTRACT 
 
The Homeodomain-interacting protein kinase 2 (HIPK2) is a nuclear 
serine–threonine kinase able to interact with homeobox proteins and 
other transcription factors. It is a sensor for various extracellular 
stimuli thus regulating several signal pathways such as apoptosis, 
embryonic development, DNA-damage response, and cellular 
proliferation. As consequence, HIPK2 alterations are involved in 
diseases such as cancer and fibrosis. HIPK2 knock-out (KO) mice 
have been generated and display a reduction in body size compared 
to WT mice and severe psychomotor behavioral abnormalities (such 
as dystonia, impaired coordination, reduced motility, clasping of 
their posterior limbs when suspended by tails and reduced responses 
to novelty) that are consistent with cerebellar defects. In this thesis, 
we have further investigated the in vivo role of HIPK2 analyzing 
other phenotypic features of the HIPK2-KO mice. 
Firstly, we investigated the cardiac phenotype consequent to the 
kinase depletion. Echocardiographic analysis performed on HIPK2-
KO mice at 4 and 12 months showed a significant reduction in 
systolic function in the adulthood, by a left ventricle fractional 
shortening (LVFS), and an increased in left ventricular (LV) 
mass/body weight (BW) ratio in HIPK2-KO mice in comparison 
with wild-type (WT) littermates. Consistently, increased expression 
levels of cardiac failure hallmarks, such atrial and brain natriuretic 
peptides, ANP, BNP, and myosin heavy chain, β-MHC were 
observed. In addition, the histological analysis of the myocardium 
was performed by WGA staining of cardiac sections at different age 
(4, 6, 12 and 18 months of age), revealing areas of fibrosis, mild 
inflammatory infiltrate and sarcoplasmic red deposits. At cellular 
level, a lot of p62/SQSTM1-positive autophagic vacuoles were 
observed in sections of hearts from KO mice at 18 months of age. In 
order to investigate the molecular mechanisms by which HIPK2 
depletion causes cardiac failure, H9C2 rat cardiomyoblasts have 
been stably silenced for HIPK2 gene expression through a 
doxycycline-inducible system. HIPK2-depleted clones showed a 
strong upregulation of ANP, BNP and β-MHC markers with respect 
to control ones, thus representing a good model to study the 
phenotype observed in KO mice.  
Abstract 
 2	
As HIPK2 protein interacts with the architectural chromatin protein 
HMGA1 (Pierantoni et al. 2001), Hmga1/Hipk2 double knock-out 
mice (DKO) have been generated in our laboratory, crossing 
Hmga1-KO (A1-KO) mice and Hipk2-KO mice, in order to 
understand the functional role of Hmga1 and Hipk2 complex in vivo.  
High Mobility Group A1 (HMGA1) is an architectural chromatin 
protein whose overexpression is a feature of malignant neoplasia 
with a causal role in cancer initiation and progression. HIPK2 and 
HMGA1 proteins physically interact, and HIPK2 phosphorylates 
HMGA1 modulating its DNA binding capacity. We observed that 
the 50% of DKO newborn mice dies within one day of life (P1) and 
autoptic examination showed that lung phenotype was characterized 
by collapsed immature sac-like alveoli and unexpanded alveolar 
spaces. Through molecular analysis, we have demonstrated that 
HMGA1 and HIPK2 positively regulate surfactant protein 
expression, since DKO mice show a strongly decreased expression 
of surfactant genes, both during embryogenesis and at birth. 
Surfactant proteins are components of lung surfactant which is 
essential for several lung functions. In addition, autoptic examination 
of DKO mice at P1 revealed also thyroid abnormalities represented 
by irregular structures of thyroid follicles devoid of colloid. 
Immunohistochemistry (IHC) and molecular analysis of thyroid late 
differentiation markers on DKO thyroid glands showed a reduction 
of expression levels of Thyroglobulin (Tg), Tireoperoxidase (Tpo) 
and Thyrotropin receptor (Tshr) DKO mice compared to control 
mice at P1. The expression of transcription factors required for the 
expression of the thyroid specific differentiation markers, FOXE1, 
PAX8 and TTF-1 were strongly reduced in thyroids from DKO at P1 
(Gerlini et al. Manuscript in submission). Altogether these data 
suggest that the lack of both Hmga1 and Hipk2 genes impairs the 
expression of PAX8 and FOXE1 in thyroid gland and, consequently, 
of thyroid differentiation markers, indicating that HMGA1/HIPK2 
interaction is crucial also for thyroid development. 
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1. INTRODUCTION 
1.1 HIPKs protein family 
The evolutionary conserved family of homeodomain-interacting 
protein kinases (HIPKs) has been identified at the end of ‘90s by a 
yeast two hybrid screening as interactors of NK homeoproteins and 
consists of four related kinases, from HIPK1 to HIPK4 (Kim et al. 
1998). HIPKs are involved in several cellular processes such as 
proliferation, cell differentiation and apoptosis (D’Orazi et al. 2002; 
Hofmann et al. 2002). All HIPK proteins are nuclear serine/threonine 
kinases localized in the nuclear speckles, but a small fraction of 
these proteins is found also in the nucleoplasm or cytosol (D’Orazi et 
al. 2002; Hofmann et al. 2002; Rinaldo et al. 2007). They are 
characterized by a strong sequence homology among them: 90% in 
kinase domain, 70% in homeobox-interacting domain and 65% in C 
terminal region (Kim et al. 1998). The high sequence homology 
among HIPK1, HIPK2 and HIPK3 proteins suggests that they may 
be functionally redundant. This seems to be confirmed by the 
phenotype of HIPK1 and HIPK2 Knock-Out (KO) mice: single 
Hipk1 or Hipk2-KOs are viable (Kondo et al. 2003; Wiggins et al. 
2004), whereas the double KO Hipk1/Hipk2 embryos die before 
birth, with various anomalies of the hematopoiesis and defects in 
blood vessel formation (Isono et al. 2006; Rinaldo et al. 2007). 
Recently, new functions related to the kinase activity of these 
proteins have been discovered. HIPK1 and HIPK2 have been found 
to phosphorylate and inhibit the carbon catabolite repressor 4 
(CCR4)-negative on TATA (NOT), a regulator of the major steps of 
the mRNA metabolism (Gil et al. 2016). An important role in insulin 
secretion and in the pathogenesis of diabetes is emerging for HIPK3 
(Shojima et al. 2012) and HIPK3 contributes to the pathogenesis of 
Huntington’s disease (HD). HD is caused by accumulation in 
neurons of mutant HTT protein (mHTT) with an expanded 
polyglutamine tract (polyQ); the accumulation is increased by 
defective autophagy. Indeed, HIPK3 has been identified as a positive 
regulator of mHTT because of its ability to inhibit autophagy (Fu et 
al. 2018). HIPK4 has been identified as an inhibitor of human 
epithelial cell differentiation, as its knock-down during the 
epithelial-differentiation of induced pluripotent stem cell (iPSCs) 
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increases the amount of skin epithelial precursors (Larribère et al. 
2017). 
 
1.2 HIPK2 structure and functions 
The best characterized member of the family is HIPK2, which is 
structurally characterized by a SUMOylation site at lysine 25, a 
Ser/Thr kinase domain, a protein–protein interaction region, called 
Homeobox-interacting domain, a region rich in proline (P), glutamic 
acid (E), serine (S) and threonine (T) that act a signal peptide for 
protein degradation (PEST region), a speckle-retention signal 
essential for the subcellular localization in nuclear bodies (NBs) and 
an auto-inhibitory domain (AID) (Fig. 1). Indeed, HIPK2 activity is 
modulated by several post-translational modifications. The 
ubiquitination provides the addition of a small protein of ubiquitin at 
a lysine of the target protein and subsequently, on a lysine of 
ubiquitin. The E3 ubiquitin ligase MDM2 catalyzes this reaction at 
the residue K1182 of HIPK2, located in the auto-inhibitory domain 
(AID) (Rinaldo et al. 2007b). Ubiquitination has been associated 
with the inactivation of HIPK2; sumoylation at lysine 25, on the 
other hand, is related to both HIPK2 activation and activity. In 
particular, following DNA damage, HIPK2 phosphorylates its E3 
SUMO ligase Pc2 that enhances HIPK2 ability to act as a 
transcriptional repressor (Roscic et al. 2006). 
 
Figure 1. Schematic representation of HIPK2 protein structure. 
Functional domains and important residues of HIPK2 protein are 
shown. K25: sumoylation site; K221: catalytic site; HID: homeobox-
interacting domain; SRS: speckle-retention signal; AID: auto-
inhibitory domain; K1182: ubiquitination site (Adapted from Nugent 
et al. 2015). 
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HIPK2 kinase activity depends on the aminoacid K221 involved in 
ATP binding, which is highly conserved (Kuwano et al. 2016). The 
importance of the lysine has been confirmed by sostitution with an 
arginine or an alanine that leads to the loss of the kinase activity: the 
mutant protein K221R (kinase dead, KD) keeps the ability to interact 
with its target proteins, but it is unable to phosphorylate both target 
protein and itself (D’Orazi et al. 2002; Hofmann et al. 2002). The 
kinase activity is important also for its nuclear bodies (NB) 
association, since HIPK2 KD shows a pan-nuclear distribution. 
HIPK2 plays a dual role in transcriptional regulation as it can repress 
or activate the transcription of many promoters. At first HIPK2 was 
identified as a transcriptional regulator and a corepressor for 
homeobox proteins. The repressive function relies on its ability to 
bind general transcriptional regulators, including methyl-DNA-
binding proteins histone acetyltransferase p300 (p300), p53 and 
cAMP response element-binding protein-binding protein (CBP) (Fig. 
2) (D’Orazi et al. 2002; Hofmann et al. 2002; Rinaldo et al. 2007). 
 
Figure 2. HIPK2 interactors. Schematic representation of HIPK2 
interactors (Adapted from Rinaldo et al. 2007).  
 
HIPK2 activating function depends on its ability to phosphorylate 
transcription factors, such as p53 (D’Orazi et al. 2002; Fusco and 
Fedele, 2007; Hofmann et al. 2002; Rinaldo et al. 2007) and activate 
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transcription factor 1 (ATF1) (Hailemariam et al. 2010). Thanks to 
the identification of its interactors, several studies have highlighted 
the importance of HIPK2 in different biological processes, such as 
embryonic development, proliferation and apoptosis. Moreover, in 
response to severe DNA damage, HIPK2 activates the apoptotic 
pathway by interacting and phosphorylating p53 at Ser46 (D’Orazi et 
al. 2002; Fusco and Fedele, 2007; Hofmann et al. 2002; Rinaldo et 
al. 2007). Indeed, in normal condition, p53 has a short half-life due 
to the binding with MDM2, an E3-ubiquitin ligase that induces p53 
proteosomal degradation. After severe genotoxic stress, HIPK2 
phosphorylates itself and p53, allowing it to break away from 
MDM2 and to accumulate in the nucleus. Here, p53 activates the 
transcription of pro-apoptotic genes as Bax and PIG3 and 
downregulates p21Waf1 (Di Stefano et al. 2005).  
However, HIPK2 regulates apoptosis also by p53-independent 
pathways. Indeed, HIPK2 can bind and phosphorylate the anti-
apoptotic factor transcription corepressor C-terminal Binding Protein 
(CtBP), inducing its degradation and sensitizing cells to apoptosis 
(Zhang et al. 2003). HIPK2 is also involved in the control of cell 
growth, as demonstrated from studies conducted on HIPK2-KO 
cells. Mouse embryonic fibroblasts (MEF) isolated from Hipk2-KO 
mice show a significant reduction in proliferation compared to WT 
counterparts (Iacovelli et al. 2009).   
Because of its ability to modulate the above mentioned cellular 
processes, HIPK2 is involved in the pathogenesis of important 
human diseases, including cancer, fibrosis and neurological diseases. 
Indeed, HIPK2 is also functionally related to the TGF-β and MeCP-2 
pathways. It can bind the transcriptional activators Smad1-4, 
involved in TGF-β pathway through the homeobox-interacting 
domain. HIPK2 expression is upregulated by TGF-β1 treatment in 
hepatic stellate cells (HSCs) and in liver fibrotic tissue. Furthermore, 
knock-down of HIPK2 inhibits TGF-β1 induced HSCs proliferation 
and decreases the expression of fibrosis markers, thus suggesting 
that HIPK2 may be a potential target for the treatment of liver fibosis 
(He et al. 2017). HIPK2 has also been identified as regulator of 
methyl-CpG binding protein 2 (MeCP2) protein stability. MeCP2 
levels are altered in several neurological diseases such as autistic 
behavior, and genetic mutations that alters MeCP2 levels are also 
responsible for Rett syndrome (caused by loss-of-function 
mutations). The discovery of druggable MeCP2 regulators, such as 
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HIPK2, may uncover new therapeutic approaches for these diseases 
(Lombardi et al. 2017).  
In addition, as previously mentioned, HIPK2 can bind and 
phosphorylate architectural transcription factors, including the High 
Mobility Group A1 (HMGA1) proteins. Several studies show that 
HMGA1 and HIPK2 share various fields of interactions, such as 
regulation of cell proliferation, apoptosis, and regulation of p53 
activity. Indeed, HIPK2 phosphorylates HMGA1a at Ser-35, Thr-52, 
and Thr-77 residues and its isoform HMGA1b at the corresponding 
sites Thr-41 and Thr-66, decreasing their binding affinity to DNA 
and altering the HMGA1-mediated regulation of gene expression 
(Zhang et al. 2007). Indeed, while HMGA1 is able to antagonize 
p53-driven transcription of apoptosis-related genes, HIPK2 is able to 
potentiate p53 pro-apoptotic activity by phosphorylating it at Serine 
46 residue. Furthermore, HMGA1, HIPK2 and p53 form a 
multiprotein complex with the transcription factor Brn-3a involved 
in the regulation of the expression of the Bcl2 anti-apoptotic gene 
(D’Orazi et al. 2002; Fusco and Fedele, 2007; Hofmann et al. 2002; 
Rinaldo et al. 2007).	
1.3 HIPK2 functions  
1.3.1 Role of HIPK2 in kidney fibrosis 
Renal fibrosis occurs in response to tissue injury: the effort to repair 
damage begins with the recruitment of inflammatory cells and with 
the activation of matrix producing cells that leads to tubular cell 
apoptosis and loss of renal function (Nugent et al. 2015). HIPK2 has 
been identified as a master regulator of kidney fibrosis in renal 
tubular epithelial cells (RTEC) infected with HIV. In fact, HIPK2 
induces expression of pro-fibrosis and apoptosis markers in RTEC, 
likely due to its role in activating p53, TGF-β, and Wnt/Notch 
pathways (Fig. 3). 
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Figure 3. HIPK2 mediated signaling pathways. HIPK2 activates 
multiple downstream signaling pathways including p53-mediated 
DNA damage signaling pathways, TGF-β/Smad, Wnt/β-catenin, 
Notch and NF-κB pathways to regulate cell growth, apoptosis, and 
development (Adapted from Fan et al. 2014). 
 
However, suppression of HIPK2 activity prevents TGF-β mediated 
induction of fibrosis markers and attenuate apoptosis (Nugent et al. 
2015). Indeed, HIPK2 levels can be regulated through seven in 
absentia homolog-1 (SIAH-1) mediated proteasomal degradation. 
This involves an accumulation of HIPK2 and a consequent 
development of fibrosis (Nugent et al. 2015). In this scenario, HIPK2 
could be a new therapeutic target for kidney disease.  
 
1.3.2 Role of HIPK2 in neurological diseases 
HIPK2 plays an important role in the development of neurological 
diseases (Fig. 4). Firstly, Doxakis et al. reported BAX- and HIPK2- 
in sensory and sympathetic neurons in response to neurotrophin 
deprivation (Doxakis et al. 2004). The expression of HIPK2 in 
dopaminergic neurons is required for TGF-mediated survival during 
programmed cell death. In fact, HIPK2-KO mice show a severe 
neurodegenerative Parkinson-like phenotype, characterized by the 
selective through apoptotic processes of the dopaminergic neurons of 
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the grey substance. In this context, HIPK2 acts on the TGFβ 
signaling pathway through the interaction with the transcription 
factor Smad3, independently from its kinase activity (Zhang et al. 
2007). These results suggest a role of HIPK2 as a survival factor in 
dopaminergic neurons. Indeed, in our lab, it has been characterized 
the expression level of HIPK2 in brain cortex, hippocampus, 
striatum and cerebellum from mice, founding that HIPK2 level 
progressively decreases with age in brain cortex, hippocampus and 
striatum, whereas increases in the cerebellum (Anzilotti et al. 2015). 
Indeed, in cerebellar Purkinje cells, lack of HIPK2 expression 
negatively interferes with Wnt/β-catenin function, giving rise to an 
impaired degradation of β-catenin (Kim et al. 2010), a hallmark of 
Parkinson’s disease, spinocerebellar ataxia, and other 
neurodegenerative diseases. Mice lacking HIPK2 display atrophic 
lobules and smaller cerebellum and a strong reduction in cerebellar 
Purkinje neurons during adulthood (Anzilotti et al. 2015). Moreover, 
HIPK2-KO mice display severe psychomotor behavioral 
abnormalities consistent with cerebellar defects, such as dystonia, 
impaired coordination, reduced motility, and clasping of posterior 
limbs of mice when suspended by the tails (Zhang et al. 2007). 
Therefore, HIPK2 may be considered a potential therapeutic target 
for treating some forms of cerebellar ataxia. 
Furthermore, the neuronal dysfunction and death at the base of many 
neurodegenerative diseases are associated with the accumulation of 
abnormally folded proteins. In particular, the alteration of protein 
homeostasis through the impairment of the ubiquitin-proteasome 
pathway could play a critical role in the pathogenesis of amyotrophic 
lateral sclerosis (ALS) and contribute significantly to the progression 
of the disease. Recently it has been demonstrated that HIPK2 is a 
possible link between stress and cell death necessary and sufficient 
to promote endoplasmic reticulum-mediated stress cell death 
(UPRRE) (Lee et al. 2016) . 
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Figure 4. Schematic representation of the recent findings about 
HIPK2 regulation and functions (Image from Conte at al. 2018). 
 
1.3.3 Role of HIPK2 in cancer 
Many evidences demonstrate that HIPK2 plays an important role in 
cancer. HIPK2 can be activated by several types of genotoxic 
damages, including ultraviolet radiation (UV), or ionizing radiation 
(IR), and its expression is triggered by antitumor drugs such as 
cisplatin (D’Orazi et al. 2002). HIPK2 role in cancer is based above 
all through the regulation of important molecules involved in cancer, 
among them the most important is p53. HIPK2 phosphorylates p53 
at Serine 46 (Ser46) and allows recruitment of histone acetylase 
(HAT) p300 for efficient p53 acetylation at lysine 382 (Lys382), 
thus inducing an increase of p53 stability (Hofmann et al. 2002). 
Interestingly, p53 activation induces caspase-6 which is responsible 
for caspase-mediated HIPK2 cleavage at positions 916 and 977 
(Gresko et al. 2006). This C-terminus truncated HIPK2 results in a 
hyperactive kinase which potentiates p53Ser46 phosphorylation and 
activation of apoptosis (Gresko et al. 2006).  
Other studies have demonstrated that HIPK2 phosphorylates β-
catenin inducing its proteasomal degradation, thus interfering with 
the transcription of several β- catenin target genes, including 
Vascular Endothelial Growth Factor (VEGF) involved in tumor 
angiogenesis and tumor growth (Puca et al. 2008). 
Moreover, HIPK2 expression is decreased in breast, thyroid and 
colon carcinomas, as demonstrated by RT-PCR analysis and genetic 
loss at HIPK2 locus 7q32-34 was found by loss of heterozigosity 
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(LOH) analysis in thyroid cancer cells. Therefore, HIPK2 inhibitions 
do exist in tumors and depend by several mechanisms including 
HIPK2 cytoplasmic localization, protein degradation, and loss of 
heterozygosity (LOH) (Lavra et al. 2011; Pierantoni et al. 2002). 
Hipk2 is a haploinsufficient tumor suppressor gene in vivo, showing 
loss of one Hipk2 allele in 30 % of the tumors and increased 
susceptibility of Hipk2+/− mice to radiation-induced thymic 
lymphoma (Mao et al. 2011). 
Few mutations of HIPK2 gene have been identified in human acute 
myeloid leukemias (AMLs), leading to an aberrant HIPK2 nuclear 
distribution inducing an impairment of p53 apoptotic transcriptional 
activity (Li et al. 2007). 
Altogether, these findings highlights the role of HIPK2 as tumor 
suppressor that is in line with the outcome of genetic HIPK2 deletion 
in mice where Hipk2−/− and Hipk2+/− mice are tumor prone and 
undergo to skin carcinogenesis by the two stage carcinogenesis 
protocol (Wei et al. 2007). However, HIPK2 amplification has been 
detected in pilocytic astrocytomas and its overexpression in a glioma 
cell line has been resulted in an increased proliferation rate (Yu et al. 
2009). In this scenario, we can say that HIPK2 has an important and 
complex role in cell proliferation, which is not easy to define. In fact 
both the loss and the gain of function of HIPK2 could promote cell 
proliferation. Therefore these studies have to be better defined and 
need to further investigations. 
 
1.4 HIPK2 Knock-out mouse models 
Several Hipk2-KO mice have been generated by several groups. 
Single Hipk2-KO mice show a reduction in body size, associated 
with severe psychomotor behavioral abnormalities consistent with 
cerebellar defects, such as dystonia, impaired coordination, reduced 
motility, and clasping of posterior limbs of mice were suspended by 
their tails, consistent failure to finish the tandem walk, poor motor 
coordination, and reduced responses to novelty (Anzilotti et al. 2015) 
(Fig. 5). 
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Figure 5. Hipk2-KO mice phenotype. Left Hipk2-KO mice were 
smaller than WT. Middle WT mice after suspension by the tail. 
Right Hipk2-KO mice showed a reduced motility in their posterior 
limbs after suspension by their tails. 
 
Moreover, HIPK2-null mice are characterized by head and snout 
crushed, a curvature of the spine, and distortion of the front and rear 
legs (Anzilotti et al. 2015). Although these phenotypes, single 
Hipk2-KO are viable and fertile. HIPK2-KO mice show cerebellum 
lobular atrophy and Purkinje cell apoptosis because of the activation 
of an apoptotic process associated with a compromised ubiquitin-
mediated proteasomal degradation pathways (Anzilotti et al. 2015). 
Moreover, Hipk1-/- Hipk2-/- double-mutants were generated from 
Isono et al. These embryos were lost between E9.5 and E12.5 
exhibiting neural tube closure defect (NTD) and exencephaly. These 
defects are due to a reduction in proliferation rate of cells of the 
neural tube and the cephalic mesoderm. Therefore, Hipk1 and Hipk2 
act in synergy to mediate growth regulation upon morphogenetic 
signals, although Hipk2 may exert a slightly dominant role (Isono et 
al. 2006).  
 
1.5 HMGA proteins 
The crucial role exerted by HIPK2 in many biological processes, 
from apoptosis to cell proliferation, is mostly due to its ability to 
bind and phosphorylate several chromatin modifiers and 
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transcription factors acting, thus acting as coactivator or corepressor 
depending on cellular context. The nuclear non-histone chromatin 
High Mobility Group A1 (HMGA1) protein represents an important 
architectural chromatin protein that interacts with HIPK2 (Pierantoni 
et al. 2001). The HMG proteins represent the largest group of non-
histone chromatin components (Bustin and Reeves, 1996), 
characterized by an enrichment in both acidic and basic (charged) 
amino acids. All HMG proteins are involved in modulating 
nucleosome and chromatin structure in different nuclear activities 
such as transcription, replication and DNA repair (Reeves et al. 
2010). In mammals HMG proteins have been classified into three 
families: HMGA, HMGB and HMGN, that are distinguished from 
each other by their DNA-binding motifs.  
The HMGA protein family is composed of two subfamilies, 
HMGA1 and HMGA2. The first subfamily consists of three proteins 
(HMGA1a, HMGA1b and HMGA1c) produced by the translation of 
alternatively spliced transcript derived from a single gene. The 
second subfamily contains only one protein (HMGA2) encoded by a 
different gene. All HMGA proteins contains three “AT-hook” 
domains, except for the HMGA1c variant which contains only two 
domains, and a C-terminal domain involved in protein-protein 
interaction (Reeves, 2010) (Fig. 6).  
 
Figure 6. Schematic representation of HMGA1 and HMGA2 
genes and proteins. Each proteins contains three basic domains, 
called AT hook (green box), with which they bind DNA, and an 
acidic carboxy-terminal region (red box) involved in protein-protein 
interactions (Image from Fusco and Fedele, 2007).  
 
Through these domains, HMGA proteins can bind to chromatin and 
proteins in a reversible way and regulate gene expression positively 
or negatively. These proteins can be modified through different post-
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translational modifications (PTMs) which control the interaction 
with DNA and other proteins influencing their biological activities. 
The PTMs include lysine acetylation, arginine/lysine methylation, 
serine/threonine phosphorylation and ADP-ribosylation (Sgarra et al. 
2008). HIPK2 can phosphorylate HMGA1 at Ser-35, Thr-52 and 
Thr-77. These HIPK2-mediated phosphorylations decrease HMGA1 
binding affinity toward DNA (Zhang et al. 2007), thus inducing an 
inhibitory effect on cell growth at the G2/M phase of the cell cycle 
(Pierantoni et al. 2001).  
1.6 HMGA expression in growth and development  
The HMGA genes are expressed at low level in normal adult tissues, 
whereas they are expressed at high level in all embryonic tissues 
(Chiappetta et al. 1996) and in malignant cells both in vivo and in 
vitro (Fusco and Fedele, 2007). Indeed, HMGA1 and HMGA2 are 
expressed at high levels in all tissues in the early stages of 
embryogenesis. The expression becomes restricted to specific organs 
in the later stage of development until to disappear (Bustin and 
Reeves, 1996).  
HMGA1 and HMGA2 proteins play an important role in embryonic 
development, adipocytic cell growth and differentiation. The 
disruption of the HMGA1 and HMGA2 genes induces an altered 
phenotype (Federico et al. 2014; Zhou et al. 1995). HMGA1 KO 
mice show a comparable or a slightly less body weight, and display 
an increased ventricular mass and ventricular wall thickness  
(Federico et al. 2014). The Hmga1-null mice exhibit a comparable 
size to the WT littermates, whereas the Hmga2-KO mice show a 
pygmy phenotype. Indeed fat tissue is drastically reduced in Hmga2-
null mice, whereas it does not seem to be modified in Hmga1-null 
mice (Zhou et al. 1995). Therefore the phenotype of the Hmga1-KO 
mice and the Hmga2-KO mice indicates that these genes exert also 
distinct functions.  
Therefore many genes are regulated by both HMGA proteins and 
several functions controlled by one of them are compensated by the 
other family member. To better investigate the role of these genes in 
development, Hmga1/Hmga2-null mice were generated. These mice 
display a more severe phenotype, characterized by a reduced vitality 
due to high rate of death in utero. Hmga1/Hmga2-null mice show 
very small size, even lower than that of the single Hmga2-KO mice, 
so they are called “superpygmy”. This phenotype depends on a lower 
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growth rate due to a decreased expression of cyclin A and cyclin E 
and a decreased activity of E2F1 (Federico et al. 2014).
Aims 
 16	
2. AIMS OF THE STUDY 
 
As previously discussed, Hipk2 is widely expressed in both 
embryonic and adult tissues, suggesting that this gene may have an 
important role in the development and/or in the homeostasis of 
several organs. To better define the role of HIPK2 in vivo, the aim of 
my thesis was to further characterize the effects of the HIPK2 
expression loss, alone or in combination with the loss of its 
interactor HMGA1, through the phenotypic analysis of both Hipk2-
KO mice and HMGA1/HIPK2 double KO mice. Histological 
examination and immunohistochemical analysis of several organs 
isolated from Hipk2-KO mice have suggested a crucial role of 
HIPK2 in cardiac homeostasis. Therefore we evaluated the role of 
HIPK2 in cardiac function through immunohistochemistry, 
echocardiography and Western blot analysis. 
Moreover, to understand the role of HMGA1/HIPK2 functional 
interaction in vivo, we generate mice carrying the disruption of both 
the Hmga1 and Hipk2 genes by crossing the HMGA1-KO (Federico 
et al. 2014) with the HIPK2-KO mice (Anzilotti et al. 2015; Rinaldo 
et al. 2012). About 50% of these mice die within 12 hours from the 
birth for respiratory failure, wherease the remaining survive and 
appear smaller than WT counterparts. For these reasons, we 
performed histological examination of DKO lungs and thyroid, and 
evaluated if HMGA1/HIPK2 complex is able to regulate the 
expression of the crucial markers involved specifically in the 
differentiation of lung and thyroid.  
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3. MATERIALS AND METHODS 
3.1 Cell culture and transfections 
H9C2 rat cardiomyoblasts (CRL-1446, ATCC, Manassas, 
Virginia) were cultured in Dulbecco’s Minimal Essential Medium 
(DMEM), low Glucose (1 g/l), 2 mML-glutamine, 1 mM sodium 
pyruvate, supplemented with 10% FBS, and 10% penicillin-
streptomycin, at 37 °C in a humidified 5% CO2 atmosphere. For 
the differentiation in cardiomyocytes, the percentage of FBS was 
decreased from 10% to 1%. For stable transfections, H9C2 
cardiomyoblasts were plated at a density of 5 × 105cells/100-mm 
tissue culture dish in antibiotic-free DMEM containing 10% FBS, 
and incubated for 24 h at 37 °C with 5% CO2. 60–70% confluent 
cells were transfected using IBAfect reagent, according to the 
manufacturer’s instructions, with a plasmid carryng shRNA 
(pINDUCER HIPK2 sh-HIPK2, kindly provided by Prof. ML 
Schmitz, University of Gieβen, Germany) targeting HIPK2 or with 
a control plasmid encoding a non-targeting shRNA (pINDUCER 
luciferase sh-CTR, kindly provided by Prof. ML Schmitz). Forty-
eight hours later, cells were selected in the presence of 0.3 µg/ml 
of puromycin. After 10 days from selection, the pools clones were 
treated with 1µg/ml of doxycycline and screened to verify the 
silencing of HIPK2.  
 
3.2 RNA extraction, RT-PCR and Quantitative real time RT-PCR 
Total RNAs from H9C2 stable pool clones were extracted using 
Trizol reagent following the manufacturer’s instruction. Five 
hundred nanograms of RNA were reverse transcribed for cDNA 
synthesis with Iscript RT-PCR system (Biorad Laboratories). 
Reverse transcription of the RNAs was followed by quantitative 
real-time PCR (q-PCR) performed with the SYBR Green real-time 
PCR master mix kit (FS Universal SYBR Green MasterRox/Roche 
Applied Science). The reactions were visualized by SYBR Green 
analysis (Applied Biosystem Inc, Foster City, CA, USA) on 
CFX96 TouchTM instrument (Biorad Laboratories). Primers used 
for gene analysis were:  
rat ANP-Forward: 5’-CTTCTTCCTCTTCCTGGCCT-3′ 
rat ANP-Reverse: 5’-TTCATCGGTCTGCTCGCTCA-3′ 
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rat BNP-Forward: 5’-TCCTTAATCTGTCGCCGCTG-3′ 
rat BNP-Reverse: 5’-AGGCGCTGTCTTGAGACCTA-3′ 
rat β-MHC- Forward: 5’-CTGACTGAACAGCTGGGCTC-3’  
rat β-MHC- Reverse: 5’- AACTCTGGAGGCTCTTCACT-3’ 
mouse/rat S18-Forward: 5’-AAACGGCTACCACATCCAAG-3  
mouse/rat S18-Reverse: 5’-CCTCCAATGGATCCTCGTTAA-3 
rat/mouse HIPK2-Forward: 5’-CCACATGTCAATTGCCTCAC-3’  
rat/mouseHIPK2-Reverse:5’-AGGTCATCGACTTTGGTTCAG-3’  
rat MLC2V-Forward: 5'-GACCCAGATCCAGGAGTTCAAGG-3'  
rat MLC2V-Reverse: 5'-CGAGGGCAGCAAACGTGTCCC-3' 
Total RNA was extracted also from several samples of cardiac 
apex of left ventricle (LV) obtained from the whole frozen hearts 
of mice at 12 months of age and from DKO thyroid and lungs, 
using the TRIzol (Invitrogen) according to the manufacturer’s 
instruction. The protocol of cDNA synthesis and qPCR are the 
same for the cells. The primers used were:  
mouse β-MHC- Forward: 5’-CGGAAACTGAAAACGGAAAG-3’ 
mouse β-MHC- Reverse: 5’-TCCTCGATCTTGTCGAACTTG-3’ 
mouseANP-Forward: 5’-CACAGATCTGATGGATTTCAAGA-3’  
mouse ANP- Reverse: 5’-CCTCATCTTCTACCGGCATC-3’ 
mouse BNP- Forward: 5’-GTCAGTCGTTTGGGCTGTAAC-3’,  
mouse BNP- Reverse: 5’-AGACCCAGGCAGAGTCAGAA-3’ 
mouse Sp-A- Forward: 5’- CTGGAGAACATGGAGACAAGG-3’ 
mouse Sp-A- Reverse: 5’- AAGCTCCTCATCCAGGTAAGC-3’ 
mouse Sp-B- Forward: 5’- AACCCCACACCTCTGAGAAC-3’ 
mouse Sp-B- Reverse: 5’- GTGCAGGCTGAGGCTTGT-3’ 
mouse Sp-C- Forward: 5’-GGTCCTGATGGAGAGTCCAC-3’ 
mouse Sp-C- Reverse: 5’-GATGAGAAGGCGTTTGAGGT-3’ 
mouse-Tg-Fw 5’-CATGGAATCTAATGCCAAGAACTG-3’ 
mouse-Tg-Re 5’-TCCCTGTGAGCTTTTGGAATG-3’ 
mouse- Tpo-Fw 5’-CAAAGGCTGGAACCCTAATTTCT-3’ 
mouse-Tpo-Re 5’-AACTTGAATGAGGTGCCTTGTCA-3’ 
mouse-Tshr-Fw 5’-TCCCTGAAAACGCATTCCA-3’ 
mouse-Tshr-Re 5’-GCATCCAGCTTTGTTCCATTG-3’ 
mouse Actin-Forward: 5’-CTAAGGCCAACCGTGAAAAG-3’ 
mouse Actin-Reverse: 5’-ACCAGAGGCATACAGGGACA-3’ 
All standards and samples were assayed in triplicate. Thermal 
cycling was initiated with an initial denaturation at 95 °C for 
5 min. After this initial step, 40 cycles of PCR were performed. 
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Each PCR cycle consisted of heating at 95 °C for 30 s for melting, 
55 °C for 30 s for annealing, and 72 °C for 30 s for the extension. 
To calculate the relative expression levels, we used the 2-
ΔΔCT method. 
 
3.3 Western blotting and antibodies 
Cells were harvested in lysis buffer NP40 2% (20 mM Tris pH 7.5 
1M, 120mM NaCl 5M, NP40 100%, 0.5 mM sodium 
orthovanadate, 10mM sodium fluoride, phenylmethylsulfonyl 
fluoride (PMSF) 1mM, aprotinin 10γ/ml, leupeptinin 10γ/ml), 
supplemented with complete protease inhibitors mixture (Roche 
Branford, CT, USA). Different cardiac sections were homogenized 
and total protein extracts were prepared with lysis buffer NP40 
2%. The lysates were incubated for 30 min in ice, and then 
centrifuged for 30 min at 14,000 × rpm. Protein concentration was 
estimated by Bradford assay, and 80 µg/lane of total proteins were 
separated on SDS gels and transferred to nitrocellulose 
membranes. Membranes were treated with a blocking buffer 
(200 mM Tris pH 7.4 2M, 9% NaCl, 0.5% Tween) containing 5% 
non-fat milk for 1 h at room temperature. Incubation with the 
primary antibody was carried out overnight at 4 °C. After 
washings, membranes were incubated with the HRP-conjugated 
secondary antibody for 1 h at room temperature. Following further 
washings of the membranes, chemiluminescence was generated by 
enhanced chemiluminescence (ECL) kit (Thermoscientific, 
Waltham, MA, USA). The primary antibodies used for western 
blotting were: anti-HIPK2 (1:100 kindly provided by Prof. ML 
Schmitz); anti-p62 (SQSTM1) (1:1000 MBL PM045); anti-β Actin 
(1:1000 sc-1615); anti γ-tubulin (1:1000, mouse monoclonal 
Sigma-Aldrich T6557); anti-calnexin (1:1000, Enzo ADI-SPA860-
F). The secondary antibodies used were: anti-goat IgG-HRP 
polyclonal antibody (6160-05, Southern Biotech), goat anti-mouse 
IgG-HRP (sc-2005) and anti-rabbit (sc-2030). 
Densitometric analyses were performed using the NIH Image 
software (Bethesda, MD, USA). 
 
3.4 Animals  
Hipk2-null mice were generated eliminating exon 3 of Hipk2 gene 
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(coding for the entire catalytic domain) as previously described 
(Anzilotti et al. 2015). Mice were genotyped using the following 
primers to amplify either wild-type or targeted alleles:  
Hipk2-Fw: 5-TAGTACCCAGGTGAACCTTGGAGT-3;  
Hipk2WT-Re: 5-GCTTCTCTCAAACTAAAGACCACGC-3;  
Hipk2KO-Re: 5-CAAAGGGTCTTTGAGCACCAGA-3. 
To generate Hmga1/Hipk2 double knock-out mice (DKO), we 
crossed A1-KO mice with K2-KO mice, generating Hmga1+/-
/Hipk2+/- mice, that were then mated, obtaining several combinations 
of Hmga1 and Hipk2 null alleles, including DKO. Mice were 
genotyped using the following primers to amplify either wild-type 
or targeted alleles: 
mouse-Hmga1-Fw 5’-GGCAGACCCAAGAAACTGG-3’  
mouse-Hmga1-Re 5’-GGCACTGCGCAGTGGTGAT-3’  
mouse-Hipk2-Fw 5’-GAGACACAGGCTCAAGATGG-3’  
mouse-Hipk2-Re 5’-TCTGCTCGTAAGGTAGGCTT-3’  
The mice included in the study were housed with no more than 5 per 
cage, maintained under identical conditions of temperature 
(21±1°C), humidity (60±5%) and light/dark cycle, and had free 
access to normal mouse chow. Experiments were performed 
according to the international guidelines for animal research. The 
experimental protocol was approved by the Animal Care Committee 
of the “Federico II” University of Naples. 
 
3.5 Echocardiography  
For ultrasound echocardiografic studies, mice (WT, n=15 and 
HIPK2-KO, n=15) at different ages (4, 6 and 12 months) were 
analyzed. Echocardiogaphy is a useful non-invasive method to 
visualize the cardiovascular structures and evaluate cardiac function 
in mice with a 30-MHz RMV-707B scanning head. Just before the 
acquisition of the echo images, the mice were anesthetized with an 
intraperitoneal (i.p.) injection of Tiletamine 5 ml/kg, Zolazepam 5 
ml/kg (Zoletil 100) and Xylazine 5 mg/Kg (Sigma-Aldrich) in order 
to minimize any suffering for the animals. The hair is removed 
applying the cream for hair removal. For echocardiography, the 
mouse is picked up in the palm of one hand. Pre-warmed echo 
transmission gel is applied to the hairless chest. The transducer is 
applied on the chest. Annulus dimensions were obtained in the 
parasternal long axis view during systole for semilunar valves, and 
the apical four-chamber view during diastole for atrioventricular 
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valves. The aortic root measurements were obtained in a modified 
parasternal long axis view during diastole. Doppler interrogation was 
performed on the atrioventricular valve inflow in the apical four-
chamber view, and semilunar valve outflow in the parasternal long 
axis view to assess for stenosis. A modified parasternal long axis 
view was required in some cases to ensure ascertainment of the 
maximum velocity. Cardiac chamber dimensions were measured, 
and ventricular function were assessed from two-dimensional 
directed M-mode echocardiographic images obtained from the 
parasternal short axis view. Doppler images were obtained from the 
apical four chamber view in accordance with consensus guidelines. 
All measurements were obtained in triplicate and averaged. 
 
3.6 Wheat germ agglutinin (WGA) and histoenzymatic staining 
Whole hearts isolated from mice of 4, 6, 12 and 18 months of age 
(HIPK2-/-, n=5 and WT, n=5) were fixed overnight in 4% aqueous 
buffered formalin, and processed for paraffin embedding. Coronal 
sections (10 µm thick) containing both right and left ventricles were 
processed. Wheat Germ Agglutinin Alexa Fluor® 488 Conjugate 
(WGA) was perfomed. WGA selectively binds to N-
acetylglucosamine and N-acetylneuraminic acid (sialic acid) residues 
in eukaryotic cells. The slices were first deparaffinized and then 
rehydrated with ethanol at decreasing concentrations. The slices 
were treated with Proteinase K, and then with Triton 1%. WGA were 
applicated on the slices and quantified under fluorescent microscopy. 
Sequential sections from each heart were stained with haematoxylin 
and eosin (H&E) (Sigma-Aldrich), nicotinamide adenine 
dinucleotide (NADH) and cytochrome oxidase (COX).  
Histological analysis of lungs and thyroid from WT and DKO at P1 
by hematoxylin and eosin staining were performed. The antibody 
used were: anti-PAX8 (Amendola et al. 2005); anti-FOXE1 (Dathan 
et al. 2002); anti-Thyroglobulin rabbit polyclonal antibody (Dako). 
The secondary antibodies used were: goat anti-rat IgG polyclonal 
antibody conjugated to horseradish peroxidase (HRP) (GtxRt-003-
DHRPX, ImmunoReagents, Inc). 
All sections were examined under light microscope (Leitz, 
DIAPLAN), and images were acquired with a digital camera (Digital 
JVC, TK-C1380).  
 
Materials and methods 
 22	
3.7 Fluorescence microscopy 
Hearts from WT and HIPK2-KO mice were included in Optimal 
Cutting Temperature (OCT), quickly frozen to reduce ice crystal 
formation and minimize morphological damage, and 7 µm slices 
were obtained through transverse cut. Immunofluorescence assays 
were carried out on heart cryosections. Tissue slices were 
permeabilized with Triton 0,2% for 5 minutes, and blocked for 1 
hour in BSA 2% and FBS 10% in phosphate-buffered saline (PBS) 
solution. Slices from WT and KO mice were stained with LC3 
antibody (1:100, 0231-100/LC3-5F10, nanoTools, Teningen, 
Germany) and p62/SQSTM1 antibody (1:100, PM045, MBL 
Medical & biological laboratories CO., LTD) for 3 hours in the dark 
at room temperature. Primary antibodies were detected with Alexa-
488 or Alexa-546 (Life Technologies, Camarillo, CA, USA) 
conjugated secondary antibodies. Nuclei were stained with DRAQ5 
Fluorescent Probe Solution (1:1000 Cell Signaling Technology). 
Images were collected using a laser scanning microscope (LSM 510 
META, Carl Zeiss Microimaging, Inc., Thornwood, NY, USA) 
equipped with a Plan Apo 63 × oil-immersion (NA 1.4) objective 
lens. Quantification and morphometric analyses and co-localization 
analysis were carried out using LSM 510 software and the drawing 
tool was used to measure the relative dimensions and cell area. 
 
3.8 Statistical analysis 
Data are expressed as means ± standard deviation (SD). Statistical 
significance between groups was assessed by Student's t test. For all 
analyses, a minimum value of p<0.05 was considered significant. 
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4. RESULTS 
 
4.1 Loss of HIPK2 induces cardiac dysfunction in mice  
Previous observations have suggested a protective role of HIPK2 in 
cardiac function. Therefore, in order to study the in vivo role of 
HIPK2, we used the HIPK2-KO mouse model. To investigate 
whether HIPK2-KO mice develop cardiac defects, transthoracic 
echocardiography was performed on groups of 15 mice both WT and 
KO at 4 and 12 months of age. A significant reduction in percentage 
of left ventricular fractional shortening (LVFS%) was observed in 
12-month old HIPK2-KO mice compared to age-matched WT, 
whereas no differences were detected at 4 months of age (Fig. 7A). 
Moreover, a significant increase in the heart weight (HW) to body 
weight (BW) ratio (HW/BW) was detected in HIPK2-KO mice with 
respect to WT mice from 12 months of age (Fig. 7B). As shown in 
figure 7C, we have observed a morphology of whole hearts of WT 
and HIPK2-KO mice at 12 months of age. In addition HIPK2-KO 
mice show smaller body size than WT counterparts (Fig. 7D). 
Collectively these data indicate that HIPK2-KO mice do not display 
early cardiac alterations, while significant reduction in systolic 
function can be detected in the middle-old mice.  
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Figure 7. Echocardiographic and morphometric analysis of 
HIPK2-KO mice. A Bar graphs of % left ventricular fractional 
shortening (LVFS%) of WT and HIPK2-KO mice at 4 and 12 
months of age (*p<0.05). B Bar graphs showing heart weight to 
body weight ratio (HW/BW) in WT and HIPK2-KO mice at 4 and 
12 months of age (*p<0.05). C Representative morphology of whole 
hearts of WT and HIPK2-KO mice at 12 months of age. D 
Representative images of WT and HIPK2-KO mice at 12 months of 
age. The same mice are shown in two different positions: lateral and 
prone positions. 
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4.2 Loss of HIPK2 induces an increase of the size of 
cardiomyocytes, cardiac inflammation and fibrosis 
In order to characterize the heart morphology of HIPK2-KO mice, an 
histological analysis of the myocardium was performed by wheat 
germ agglutinin (WGA) staining of cardiac sections at different age 
(4, 6, 12, 18 months). As shown in figure 8A and 8B, cross-sectional 
area of cardiomyocytes from HIPK2-KO was significantly increased 
at 18 months of age compared to WT, whereas no differences were 
detected in younger mice. These data suggest that loss of HIPK2 
induces an age-dependent hypertrophy of cardiomyocytes in HIPK2-
KO mice.  
To better characterize the phenotype, we performed morphologic and 
histoenzymatic staining of cardiac muscle sections. Hematoxylin and 
eosin (H&E) was performed to evaluate heart morphology, while 
cytochrome oxidase (COX) and nicotinamide adenine dinucleotide 
(NADH) and stainings were performed to evaluate mitochondrial 
activity. H&E revealed a mild inflammatory infiltrate of 
lymphocytes in myocardium and a moderate fibrosis in HIPK2-KO 
mice at 18 months compared to WT controls (Fig. 8C upper panel). 
Moreover, COX staining revealed an overall normal mitochondrial 
activity, but several negative or partially negative fibers for COX 
activity were observed in HIPK2-KO mice (Fig. 8C middle panel). 
NADH staining showed several fibers with subsarcolemmal positive 
deposits (ragged blue fibers) (Fig. 8C lower panel).  
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Figure 8. Histological analysis of the size of cardiomyocytes, 
inflammation and fibrosis in HIPK2-KO mice. A Representative 
images of WGA staining of sections from WT and HIPK2-KO mice 
at 4 up to 18 months of age. Scale bar= 60 µm. B Quantification of 
cross sectional area of cardiomyocytes in the different experimental 
groups (*p < 0.05 vs. 4 months HIPK2-/-, n=4 hearts/groups). C 
Representative H&E, COX and NADH staining of LV sections from 
WT and HIPK2-KO mice at 18 months of age (40x magnification); 
scale bar= 100 µm. Arrow indicates fibrosis area. 
 
4.3 Expression levels of cardiac failure markers are increased in 
HIPK2-KO mice 
The above results clearly indicate that HIPK2-KO mice display 
alterations of heart. To assess whether morphological alterations are 
associated with changes in expression of molecular markers of 
cardiac failure and dysfunction, quantitative PCRs (qRT-PCR) for 
ANP, BNP and β-MHC were performed on cardiac apex of LV 
samples from WT and HIPK2-KO mice at 12 months. The 
mammalian heart expresses two closely related natriuretic peptide 
(NP) hormones, ANP and BNP. Plasma levels of BNP are used as 
diagnostic and prognostic markers for hypertrophy and heart failure 
(HF), and both ANP and BNP are widely used in biomedical 
research to assess the hypertrophic response. 
As shown in figure 9, a significant increase of ANP, BNP and β-
MHC expression was observed in HIPK2-KO mice. 
Overall, these results are consistent with the cardiac dysfunctions 
observed by echocardiography and histology, and demonstrate that 
HIPK2 loss causes myocardial alterations leading to cardiac failure. 
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Figure 9. qRT-PCR analysis of cardiac failure markers in 
HIPK2-KO mice. RNA extracted from cardiac apex of LV samples 
of WT and HIPK2-KO at 12 months of age have been analyzed by 
qRT-PCR for ANP, BNP and β-MHC expression levels. The 18S 
ribosomal RNA housekeeping gene was used for normalization 
(*p<0.05).  
 
4.4 Altered autophagic pathway in HIPK2-KO mice  
The presence of sarcoplasmatic red deposits in the myocardium of 
HIPK2-KO mice may be attributable to autophagic vacuoles 
therefore, we evaluated the expression levels of p62/SQSTM1, an 
autophagic marker responsible for the addressing proteins to the 
autophagosomes. Immunofluorescence (IF) of heart cryosections of 
cardiomyocytes of WT and HIPK2-KO at 18 months of age, 
revealed an increased number of p62/SQSTM1 positive structures in 
HIPK2-KO mice (Fig. 10A). Consistently, levels of p62/SQSTM1 
were increased in HIPK2-KO mice compared to WT mice at 12 
months of age, as shown by Western blotting analysis (Fig. 10B). 
These data indicate that the loss of HIPK2 induces an alteration of 
the autopaghic pathway in mice. 
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Figure 10. Evaluation of p62/SQSTM1 in HIPK2-KO mice. A 
Representative immunofluorescente images of heart cryosections of 
WT and HIPK2-KO mice at 18 months of age stained with 
p62/SQSTM1 antibody. Scale bar= 12 µm. B Upper panel: 
Immunoblot detection of p62/SQSTM1 from lysates extracted from 
WT and HIPK2-KO heart sections of mice at 12 months of age. 
Calnexin was used as loading control. The molecular weight of 
Results 
 30	
protein markers is indicated. The quantification of Western blotting 
is shown in lower panel. 
 
4.5 HIPK2 protein levels increase during differentiation of 
cardiomyoblasts  
The above described data suggest a role of HIPK2 protein in cardiac 
homeostasis. To confirm this hypothesis, firstly we evaluated HIPK2 
expression levels during cardiomyocyte differentiation in vitro. As a 
model system, we used the H9C2 rat cardiomyoblasts, which have 
been exstensively characterized. H9C2 cells were cultered in 
DMEM. For their differentiation, they were initially grown with 
supplement of 10% FBS DMEM low glucose (1gr/l) for 3 days and 
switched to differentiation medium (1% FBS DMEM low glucose 
1gr/l) for seven days (Comelli et al. 2011).  
To evaluate if HIPK2 expression changes during the differentiation 
of H9C2 cells, I performed RNA extraction from rat cardiomyoblasts 
at day zero and from cardiomyocytes at days three and seven of 
differentiation. qRT-PCR analysis, performed using as control the 
differantiation marker ventricular myosin light chain 2 (MLC2V), 
showed that the endogenus HIPK2 is expressed at basal levels in 
cardiomyoblasts (day zero) and increases in cardiomyocytes after 
three and seven days of treatment with the diffentiating medium 
(Fig. 11A). In parallel, western blot analysis performed on total 
cellular extracts at day zero and at day seven showed an increase of 
HIPK2 protein level (Fig. 11B). Moreover, we asked whether HIPK2 
gene expression levels would change upon hypertrophic stimuly. In 
fact, it is known that cardiac hypertrophy is caused by an increased 
glucose uptake into the cardiac myocytes that determines a high 
glucose-mediated oxidative stress into the cardiomyocytes (Kagaya 
et al. 1990). This increased glucose uptake is mostly due to an 
imbalance of the translocation of GLUT1 and GLUT4 glucose 
transporters from intracellular membranes to the cell surface of the 
myocytes with a GLUT1/GLUT4 ratio favoring GLUT1 (Slot et al. 
1991). On this basis, to induce hypertrophy, after 7 days of culture in 
differentiation conditions with DMEM 1% FBS 1gr/l glucose, H9C2 
cells were treated for 24 hours with DMEM 1% FBS 4gr/l glucose. 
Interestingly, the hypertrophic stimulus induces a decrease in HIPK2 
expression (Fig. 11C and 11D). These results strongly suggest that 
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HIPK2 could exert a protective role against induced cardiac 
hypertrophy.  
 
Figure 11. HIPK2 expression during cardiac differentiation. A 
RNAs extracted from H9C2 cells at different days were analyzed by 
qRT-PCR for HIPK2 and MLC2V expression levels. The 18S 
ribosomal RNA housekeeping gene was used for normalization 
(*p<0.05; **p<0.01). B Protein extracted from H9C2 at 0 and 7 days 
were analyzed by Western blotting for HIPK2 protein expression. 
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Anti-γ-tubulin was used as loading control. C HIPK2 mRNA levels 
in H9C2 undifferentiated, differentiated and differentiated treated 
with an hypertrophic stimuli, the glucose, as measured by qRT-PCR. 
The amount of HIPK2 mRNA was normalized with respect to the 
amount of 18S ribosomal RNA housekeeping gene (*p<0.05; 
**p<0.01). D Immunoblot detection of HIPK2 from lysates extracted 
from H9C2 cells treated with an hypertrophic stimuli, the gluose. To 
monitor equal loading of protein in the gel lanes, the blot was probed 
using anti-γ-tubulin antibody. 
 
Finally, to evaluate the effect of HIPK2 down-regulation on 
cardiomyocyte differentiation, H9C2 cells were stably transfected 
with a plasmid coding for HIPK2 short hairpin RNA (shRNA). It 
interferes wth the expression of HIPK2 and it is activated by 
doxycycline treatment. First, I used a pool clone to analyze HIPK2 
protein expression. I focused on one pool showing about 50% of 
reduction of HIPK2 expression (Fig. 12A). I evaluated the 
expression levels of cardiac failure hallmarks, ANP, BNP and β-
MHC upon HIPK2-knock-down by qRT-PCR analysis. As observed 
in figure 12B, a strong increase of ANP, BNP, and β-MHC mRNA 
levels were revealed confirming the evidence that HIPK2 may have 
a positive role in the induction of cardiac dysfunction. 
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Figure 12. HIPK2 silencing promotes expression of cardiac 
failure markers in H9C2 cells. A Proteins extracted from H9C2 sh-
HIPK2 were analyzed by Western blotting for HIPK2 protein 
expression. Anti-β actin was used as loading control. B RNA 
extracted from sh-HIPK2 H9C2 cells analyzed by qRT-PCR for 
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ANP, BNP and β-MHC expression levels. The 18S ribosomal RNA 
housekeeping gene was used for normalization (*p<0.05; **p<0.01). 
 
4.6 DKO mice show respiratory failure at birth and a decrease of 
expression of surfactant proteins in lung  
As HIPK2 protein interacts with the architectural chromatin protein 
HMGA1 (Pierantoni et al. 2001), we have generated Hmga1/Hipk2 
double knock-out mice (DKO) to determine the functional role of 
Hmga1 and Hipk2 interaction in vivo. In collaboration with Prof. 
Fusco who has provided us single HMGA1-KO mice, we have 
crossed Hmga1-KO (A1-KO) mice and Hipk2-KO (HIPK2-KO) 
mice. The resulting double heterozygous were crossed to obtain the 
DKO mice. To verify the genotype of generated mice, DNA 
extracted from pieces of murine tails was amplified by PCR, using 
specific primers for WT and KO alleles of Hmga1 and Hipk2 genes. 
The amplified fragments were separated by electrophoresis on 
agarose gel to confirm the absence of HMGA1 and HIPK2 
expression in DKO mice. We analyzed also, the phenotype of the 
DKO puppies. Observing the newborn mice, we have found that 
about 50% of DKO mice died within 12 hours after birth (P1). These 
mice appeared also smaller than the WT counterparts (Fig. 13A). 
Interestingly, also DKO mice that survive displayed smaller size and 
lower weight than their WT littermates (Fig. 13B).  
Since DKO mice which died at P1 were cyanotic at birth and showed 
breathing difficulties, we hypothesized that the DKO could present 
lung abnormalities. To test this hypothesis, a post-mortem 
histological examination of DKO lungs was performed in 
comparison with WT mice at P1. Mice were sacrificed by CO2 
asphyxia by following university procedures approved by Animal 
Care Committee of the “Federico II”, University of Naples. To 
perform the experiments, lungs from WT and DKO mice were 
included in paraffin and 7 µm sections were cut. By staining with 
hematoxylin and eosin, we observed that most of lungs from DKO 
mice were characterized by an immature pulmonary phenotype: 
these lungs presented collapsed immature sac-like alveoli (Fig. 13C) 
and unexpanded alveolar spaces containing abundant floccular 
eosinophilic material. This phenotype appears only in DKO lungs, 
whereas lungs from WT did not present abnormalities (Fig. 13D). 
Pulmonary surfactant is a surface-active lipoprotein complex 
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producted by type II alveolar cells: this complex is found in the fluid 
covering the alveolar surface of the lungs, where it plays several 
important roles. First of all, surfactant prevents alveolar collapse, 
and preserves bronchiolar patency during normal and forced 
respiration (Griese, 1999). It is well known that the absence of 
surfactant proteins results in lethal neonatal respiratory distress in 
both mice and human, and immunohistochemical studies 
demonstrated a lack of SP-A in infants dying before 48h of life 
(Markgraf et al. 1990). To test whether the HMGA1 and HIPK2 
absence leads to an impaired expression of surfactant proteins, we 
performed quantitative RT-PCR (qRT-PCR) on total RNA extracted 
from WT and DKO lungs at P1. Sp-A and Sp-B expression was 
undetectable in all the DKO analyzed mice, and Sp-C expression was 
drastically reduced of about 58% compared to the WT mice (Fig. 
13E). These results demonstrate that HMGA1 and HIPK2 proteins 
are required for the proper expression of surfactant proteins and, 
therefore, their cooperation is essential for the proper development 
of the lung. 
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Figure 13. DKO mice display phenotypic alterations and a 
reduced surfactant expression levels in lungs. A Phenotypic 
differences between WT and DKO newborn puppies died at P1. B 
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DKO mice that survive appeared smaller and weight less than WT 
counterparts. In the left panel representative images of WT and DKO 
mice at 3 and 17 weeks of life (***) represent p value < 0.001. C-D 
Histological analysis of WT and DKO lungs at P1 by hematoxylin 
and eosin staining (200x magnification). E RNAs extracted from 
WT and DKO lungs at P1 were analyzed by qRT-PCR for Sp-A, Sp-
B and Sp-C expression. The actin expression level has been used for 
data normalization (** p<0.01). 
 
4.7 DKO mice display thyroid dysfunction 
Since the DKO newborn puppies that survive at P1 appear smaller 
than the WT counterparts, we hypothesized a possible role of Hmga1 
and Hipk2 interaction also in the thyroid function, because both lung 
and thyroid organs derive from the same embryonic layer, the 
endoderm. Moreover, during the perinatal period, adequate levels of 
thyroid hormones are critical to promote proper lung maturation and 
the proper development of lung and thyroid involves one common 
mediator, such as NKX2-1 (also called TTF-1) (Lazzaro et al. 1991). 
NKX2.1 is essential for brain, thyroid and lung development and 
differentiation (Minoo et al. 1995) and it regulates TG, TPO, and 
TSH gene expression (Civitareale et al. 1993; Francis-Lang et al. 
1992). Furthermore, it is required for Sp-A, Sp-B, Sp-C and its 
absence causes lack of the lung parenchyma (De Felice et al. 2003; 
Kelly et al. 1996; Park et al. 2004). 
To investigate this hypothesis, thyroid glands from DKO mice at P1 
were compared to those from WT. Sections of neck containing the 
thyroid gland from WT and DKO mice at P1 were included in 
paraffin and 7 µm slices were obtained. By H&E staining, we 
observed that thyroid from DKO was characterized by an irregular 
structure and the absence of colloid (Fig. 14A and 14B). Then, we 
asked whether differentiated thyroid follicular cells were present in 
DKO thyroid glands. It is known that differentiated thyroid follicular 
cells, are characterized by the coexpression of NKX2.1(Lazzaro et 
al. 1991), FOXE1 (Zannini et al. 1997) and PAX8 (Plachov et al. 
1990), which remain expressed after differentiation and are a 
hallmark of differentiated thyroid follicular cells. To analyze the 
expression of thyroid markers, immunohistochemistry analysis were 
performed on thyroid sections from DKO and WT mice at P1. 
FOXE1 and PAX8 protein levels were strongly reduced in thyroids 
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from DKO in comparison with WT as shown in figure 14 C-F. 
Then, I performed IHC to evaluate the presence of colloid in DKO 
thyroids and qRT-PCR analysis to evaluate expression levels of late 
differentiation markers as thyroglobulin (Tg), thyroid peroxidase 
(Tpo) and thyrotropin receptor (Tshr). The expression of Tpo and 
Tshr mRNA were significantly reduced in DKO mice compared to 
the control mice at P1 (Fig. 14G). These data demonstrate that 
HMGA1 and HIPK2 have a key role in the thyroid function since 
their absence leads to a reduced expression of Pax8 and Foxe1 genes 
and this is responsible for the reduced amount of late thyroid 
markers TG, TPO and TSHr.  
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Figure 14. DKO leads to altered thyroid phenotype and impaired 
expression of thyroid markers in mice at P1. A-B Histological 
analysis of WT and DKO thyroid glands at P1 by hematoxylin and 
eosin staining revealed an altered phenotype in DKO mice (200x 
magnification). C-F IHC for FOXE1 and PAX8 expression were 
performed on WT and DKO sections of neck containing the thyroid 
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(20x magnification). G qRT-PCR on RNAs from WT and DKO 
mice at P1 was performed to evaluate the expression levels of Tg, 
Tpo and Tshr genes. Statistical differences are represented *p <0.05; 
***p<0.001.
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5. DISCUSSION AND CONCLUSIONS 
 
During my PhD, I have investigated the in vivo role of the loss of 
HIPK2 taking advantage from HIPK2-KO mice. In particular from 
previous results I investigated the role of HIPK2 loss in cardiac 
homeostasis and the role of HMGA1/HIPK2 complex in vivo. 
Echocardiographic analysis of HIPK2-KO mice has revealed a 
reduced cardiac function, evidenced by left ventricle fractional 
shortening (LVFS) at 12-months of age, whereas no differences with 
respect to WT mice have been detected at 4 months of age, 
indicating a significant reduction in systolic function in the 
adulthood (Fig. 7A). Indeed, expression levels of cardiac failure 
hallmarks, atrial and brain natriuretic peptides (ANP and BNP) and 
myosin heavy chain (β−MHC), were strongly increased (Fig. 9). 
Moreover, an histological analysis of the myocardium has revealed 
areas of fibrosis, mild inflammatory infiltrate and sarcoplasmic red 
deposits in cryosections of hearts from HIPK2-KO mice at 18 
months of age (Fig. 8C). At cellular level, a lot of autophagic 
vacuoles p62/SQSTM1 positive have been observed (Fig. 10A). 
Therefore, the loss of HIPK2 induces cardiac dysfunction in mice 
that could be correlated to an altered autophagic pathway, indicating 
a critical role of HIPK2 in heart function. However, we did not find 
any variation in the expression levels of other autophagic proteins 
such as Microtubule-associated proteins 1A/1B light chain 3B (LC3) 
(data not shown). 
The HIPK2-depleted cellular model of rat cardiomyoblasts H9C2 
generated by us represents a tool to verify if HIPK2 could play a role 
in cardiac differentiation. We observed that the endogenus HIPK2 is 
expressed at basal levels in cardiomyoblasts and increases in 
cardiomyocytes at three and seven days of treatment with the 
diffentiating medium (Fig. 11A) and the expression levels of cardiac 
failure hallmarks, such as ANP, BNP and β-MHC were strongly 
increased after HIPK2 knock-down (Fig. 12B). 
Altogether, these findings suggest that HIPK2 is required to maintain 
normal cardiac homeostasis and that its deletion leads to cardiac 
dysfunction; indeed it has previously demonstrated the role of 
HIPK2 in skeletal muscle cells differentiation (De la Vega et al. 
2013). Moreover, a recent study has highlighted the protective role 
of HIPK2 from pathological hypertrophy in cardiomyocytes (Guo et 
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al. Circulation 2018). In fact, Guo et al. have reported a decreased 
contractile function and the enlarged of left ventricle internal 
dimension in αMHC-Cre driven cardiomyocyte-specific HIPK2-KO 
mice. Furthermore, tamoxifen-induced deletion of HIPK2 in the 
adult mouse heart (KO, HIPK2flox/flox αMHC-MerCreMer/) resulted in a 
decrease of heart function with a significant reduction of fractional 
shortening (FS) and ejection fraction (EF). This finding suggest that 
HIPK2 is required to mantain normal cardiac homeostasis and its 
deletion leads to cardiac dysfunction. 
Cardiac dysfunction occurs in response to stresses from 
neurohumoral activation and hemodynamic overload. Persistent 
cardiac dysfunction usually progresses to chronic heart failure, 
which has a high mortality rate. Initially, the heart undergoes 
adaptive morphological changes that result in compensated 
hypertrophy to maintain cardiac output. Sustained hypertrophy is 
irreversible and inevitably results in decompensated heart failure (Li 
et al. 2018). Therefore, we also evaluated whether HIPK2 gene 
expression levels would change upon hypetrophic stimuly. 
Interestingly, the hypertrophic stimulus such as the glucose 4gr/l, 
induces a strong decrease in HIPK2 expression (Fig. 11C and 11D). 
These results strongly suggest that HIPK2 could exert a protective 
role against induced cardiac hypertrophy and that its loss could cause 
an hypertrophic phenotype of the heart.  
Pathological left ventricular hypertrophy (LVH) is a hallmark feature 
of a number cardiovascular diseases and is strongly associated with 
increased risk of developing heart failure (Lewis et al. 1990). In 
response to stress, such as hypertension and pressure overload, 
several cellular modifications lead to cardiac remodeling (Burchfield 
et al. 2013). Despite the critical role of LVH in the development of 
cardiac dysfunction, the mechanisms underlying cardiac hypertrophy 
in response to pressure overload still remain not completely 
understood yet (Schiattarella et al. 2018). Therefore, further 
investigations of molecular mechanisms underlying cardiac 
hypertrophy, may allow to find new therapeutic approaches for this 
disease, involving new target molecules, including HIPK2.  
As HIPK2 protein interacts with the architectural chromatin protein 
HMGA1 (Pierantoni et al. 2001), Hmga1/Hipk2 double knock-out 
mice (DKO) have been generated in order to understand the 
functional role of Hmga1 and Hipk2 complex in vivo. 
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As discussed in the Introduction section, it is know that Hipk2 gene 
is expressed from 15.5 days post coitum (d.p.c.) during 
embriogenesis and expressed in retinic cells, myoblasts and 
telencephalic neuroblasts during mouse embryogenesis. Conversely, 
it is ubiquitously expressed in murine and human adult tissues. 
Moreover, HIPK2 expression has been found down-regulated in 
breast and thyroid human carcinomas (Pierantoni et al. 2002). 
Instead, HMGA1, which is involved in embryogenesis, neoplastic 
transformation and adipocytic differentiation, is abundantly 
expressed in the all stages of embryonic development and begine to 
decline at 17-18 d.p.c., when HIPK2 is expressed (Pierantoni et al. 
2002). 
Therefore in my PhD thesis, I have also investigated the functional 
role of HMGA1/HIPK2 interaction in vivo and the phenotype of 
HMGA1 and HIPK2 DKO mice. Surprisingly, 50% of 
HIPK2/HMGA1 DKO mice show perinatal lethality associated to 
respiratory distress. In fact, the maturation of the lung alveolar 
epithelium is delayed in the DKO mice, as indicated by post-mortem 
IHC analysis showing collapsed immature sac-like alveoli indicating 
a compromised lung development (Fig. 13A, 13C and 13D). 
HMGA1/HIPK2 proteins could be involved in the regulation of 
surfactant expression. Indeed, in the DKO mice, Sp-A and Sp-B 
expression was almost undetectable while Sp-C expression was 
strongly decreased with respect to their WT counterpart (Fig. 13E). 
This leads to a delay in the maturation of lung epithelial cells that we 
observed in DKO lungs. Altogheter these data suggest that the lack 
or the strong reduction of surfactant expression caused by the loss of 
Hmga1 and Hipk2 expression is responsible for the death of DKO 
mice for respiratory distress. It is worthnote that mutations in the Sp-
B gene are associated with fatal respiratory distress in the neonatal 
period, and mutations in the Sp-C gene are more commonly 
associated with interstitial lung disease in older infants, children, and 
adults (Wert et al. 2009). Moreover, it has been previously reported 
that HIPK2 regulate negatively the hypoxia-inducible factor-1α 
(HIF-1α) (Nardinocchi et al. 2009). HIF-1α is responsible, among 
other transcription factors, for fetal lung development as it allows the 
fetus to quickly adapt to variation of oxygen concentrations. Indeed, 
lung-specific HIF-1α KO leads to perinatal death in mice associated 
to impaired alveolar epithelial differentiation with consequent loss of 
surfactant protein expression (Saini et al. 2008). Therefore, the loss 
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of Hipk2 expression may affect SP levels also by modulating HIF-
1α. 
In addition, Hmga1/Hipk2 DKO mice showed other phenotypic 
features associated to the development of the thyroid, in terms of 
lack of colloid accumulation in thyroid follicles and failure of the 
normal thyroid differentiation. Indeed, the autoptic examination of 
thyroid glands of DKO mice at P1 revealed thyroid abnormalities. 
The specific markers of thyroid differentiation, such as 
Tireoperoxidase (Tpo), Thyrotropin receptor (Tshr) and 
Thyroglobulin (Tg), are downregulated in DKO mice at P1, with the 
TG relocated mostly at the margins of the gland (Fig. 14A-F). The 
reduced expression of two thyroid specific transcription factors 
TTF2 and PAX8, that have been described as crucial for thyroid 
development and differentiation, likely accounts for this phenotype 
(Fig. 14G). Altogether these data suggest that lack of both Hmga1 
and Hipk2 genes impairs the expression of PAX8 and FOXE1 in 
thyroid gland and, consequently, of thyroid differentiation markers, 
indicating that HMGA1/HIPK2 interaction is important also for 
thyroid development (Gerlini et al. Manuscript in submission). 
Moreover the association between lung and thyroid dysfunctions is 
not surprising, since both organs derive from the same embryonic 
layer, the endoderm.  
In conclusion, the data obtained during my PhD thesis suggest a new 
putative role for the loss of HIPK2 in the pathogenesis of cardiac 
failure, and, in combination with the loss of HMGA1, of lung and 
thyroid dysfunction. 
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